Rubella Treatment Market size is projected to witness around 6.4% CAGR during the forecast period i.e., between 2024-2036. The growth of the market can be largely attributed to the growing number of cases of rubella that results from high transmission ability of togavirus via air. Along with this, launch of several government initiatives associated with research and development of sophisticated diagnostic techniques, especially in emerging economies such as China and India, is expected to offer abundant opportunities for market growth in the near future. Furthermore, high risk of major complications in rubella infected pregnant women, and escalating government initiatives to include rubella vaccinations in national health programs, targeted mainly towards children and young adults, are also significant factors projected to augment the growth of the rubella treatment market in the upcoming years. According to the World Health Organization, 168 out of 194 countries introduced rubella vaccines in their health programs and the global coverage was about 69 percent as of December 2018. 14,621 cases of the disease were reported in 151 countries that same year.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
6.4% |
|
Regional Scope |
|
The market is segmented by drug type into analgesic, nonsteroidal anti-inflammatory drugs, and others, out of which, the analgesic segment is anticipated to hold the largest share in the global rubella treatment market. This can be accounted to the high demand for analgesics across the globe owing to their ability to effectively reduce fever and relieve several kinds of mild to moderate pain. Additionally, on the basis of route of administration, the segment for oral route is predicted to grab the most significant share during the forecast period, which can be credited to its advantages, including patient compliance, non-invasiveness, and convenience of drug administration. Apart from these, most of the medicines for managing the symptoms of rubella are administered via oral route, which is also assessed to boost the segment’s growth in the future.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Route of Administration |
|
|
By End User |
|
On the basis of geographical analysis, the global rubella treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market North America industry is estimated to hold largest revenue share by 2036, on account of growing levels of awareness about rubella, high healthcare spending, and rising number of drug manufacturing facilities in the region. The Centers for Medicare and Medicaid Services stated that in 2019, the healthcare expenditure in the United States reached a value of USD 11,582 per person in 2019. It accounted for 17.7 percent of the nation’s GDP that same year.
In addition, Europe is anticipated to be the second largest shareholder in the market during the forecast period owing to stringent regulatory framework and government guidelines regarding the health of mother and child. Moreover, the rubella treatment market in Asia Pacific is expected to witness noteworthy growth by the end of 2030, which can be credited to the increasing government initiatives to develop novel vaccines and therapies, and relatively low cost of drug production in the region.
August 2021- GlaxoSmithKline announced that it has submitted a license application to the U.S Food and Drug Administration for PRIORIX, which is targeted for immunization against measles, mumps and rubella (MMR).
July 2019- Measles outbreak in the United States helped in boosting the sales of Merck’s vaccine by 58 percent in the second quarter of the year.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?